Cargando…

A small molecule inhibitor of HER3: a proof-of-concept study

Despite being catalytically defective, pseudokinases are typically essential players of cellular signalling, acting as allosteric regulators of their active counterparts. Deregulation of a growing number of pseudokinases has been linked to human diseases, making pseudokinases therapeutic targets of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Colomba, Audrey, Fitzek, Martina, George, Roger, Weitsman, Gregory, Roberts, Selene, Zanetti-Domingues, Laura, Hirsch, Michael, Rolfe, Daniel J., Mehmood, Shahid, Madin, Andrew, Claus, Jeroen, Kjaer, Svend, Snijders, Ambrosius P., Ng, Tony, Martin-Fernandez, Marisa, Smith, David M., Parker, Peter J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Portland Press Ltd. 2020
Materias:	Cancer
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7489893/ https://www.ncbi.nlm.nih.gov/pubmed/32815546 http://dx.doi.org/10.1042/BCJ20200496

Ejemplares similares

Inhibitor-induced HER2-HER3 heterodimerisation promotes proliferation through a novel dimer interface
por: Claus, Jeroen, et al.
Publicado: (2018)

Radiosensitization of HER2-positive esophageal cancer cells by pyrotinib
por: Lian, Xiangyao, et al.
Publicado: (2020)

Targeting of the HER2/HER3 signaling axis overcomes ligand‐mediated resistance to trastuzumab in HER2‐positive breast cancer
por: Watanabe, Satomi, et al.
Publicado: (2019)

Using the HER2/CEP17 FISH Ratio to Predict Pathologic Complete Response Following Neoadjuvant Anti-HER2 Doublet Therapy in HER2+ Breast Cancer
por: Lander, Eric M, et al.
Publicado: (2022)

Measuring EGFR Separations on Cells with ∼10 nm Resolution via Fluorophore Localization Imaging with Photobleaching
por: Needham, Sarah R., et al.
Publicado: (2013)

Correlation of ER, PR, and HER2 at the protein and mRNA levels in Asian patients with operable breast cancer
por: Chen, Chih-Jung, et al.
Publicado: (2022)

HER2 as a target in invasive urothelial carcinoma
por: Bellmunt, Joaquim, et al.
Publicado: (2015)

HER2 status and disparities in luminal breast cancers
por: Holowatyj, Andreana N., et al.
Publicado: (2016)

De Novo Versus Recurrent HER2‐Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry
por: Tripathy, Debu, et al.
Publicado: (2019)

Real-World Impact of Adjuvant Anti-HER2 Treatment on Characteristics and Outcomes of Women With HER2-Positive Metastatic Breast Cancer in the ESME Program
por: Le Du, Fanny, et al.
Publicado: (2023)

Applying Precision Medicine to Ovarian Cancer: Proof-of-Principle for a “Molecular Second Look”
por: Schwartz, Melissa, et al.
Publicado: (2018)

Underuse of Anthracyclines in Women with HER-2(+) Advanced Breast Cancer
por: Montemurro, Filippo, et al.
Publicado: (2010)

ERBB3 (HER3) is a key sensor in the regulation of ERBB-mediated signaling in both low and high ERBB2 (HER2) expressing cancer cells
por: Choi, Byung-Kwon, et al.
Publicado: (2012)

Novel Anti-HER2 Antibody-Drug Conjugates Versus T-DM1 for HER2-Positive Metastatic Breast Cancer After Tyrosine Kinase Inhibitors Treatment
por: Ji, Chenchen, et al.
Publicado: (2023)

Hydrophobic Fluorescent Probes Introduce Artifacts into Single Molecule Tracking Experiments Due to Non-Specific Binding
por: Zanetti-Domingues, Laura C., et al.
Publicado: (2013)

Relationship of HER2 Alteration and Microsatellite Instability Status in Colorectal Adenocarcinoma
por: Qiu, Miao‐Zhen, et al.
Publicado: (2021)

Rare cancers of unknown etiology: lessons learned from a European multi-center case–control study
por: Lynge, Elsebeth, et al.
Publicado: (2020)

A Systematic Investigation of Differential Effects of Cell Culture Substrates on the Extent of Artifacts in Single-Molecule Tracking
por: Zanetti-Domingues, Laura C., et al.
Publicado: (2012)

HER2-HER3 dimer quantification by FLIM-FRET predicts breast cancer metastatic relapse independently of HER2 IHC status
por: Weitsman, Gregory, et al.
Publicado: (2016)

Recognition of HER2 expression in hepatocellular carcinoma and its significance in postoperative tumor recurrence
por: Shi, Ji‐Hua, et al.
Publicado: (2019)

HER2 exon 27 mutations predict worse survival of breast cancer patients, especially in HER2‐negative patients
por: Si, Pilei, et al.
Publicado: (2017)

A global sampler of single particle tracking solutions for single molecule microscopy
por: Hirsch, Michael, et al.
Publicado: (2019)

Reduced risk of breast cancer associated with recreational physical activity varies by HER2 status
por: Ma, Huiyan, et al.
Publicado: (2015)

Reproducibility of Her2/neu scoring in gastric cancer and assessment of the 10% cut-off rule
por: Behrens, Hans-Michael, et al.
Publicado: (2015)

Protein lysine methyltransferase SMYD3 is involved in tumorigenesis through regulation of HER2 homodimerization
por: Yoshioka, Yuichiro, et al.
Publicado: (2017)

HER2 Expression Associated with Clinical Characteristics and Prognosis of Urothelial Carcinoma in a Chinese Population
por: Zhou, Li, et al.
Publicado: (2023)

HER2-PI9 and HER2-I12: two novel and functionally active splice variants of the oncogene HER2 in breast cancer
por: Hart, Vic, et al.
Publicado: (2021)

EGFR, KRAS, BRAF, and HER-2 molecular status in brain metastases from 77 NSCLC patients
por: Villalva, Claire, et al.
Publicado: (2013)

Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer
por: Yu, Anthony F., et al.
Publicado: (2016)

Enhanced humoral immunity in breast cancer patients with high serum concentration of anti‐HER2 autoantibody
por: Sato, Yasufumi, et al.
Publicado: (2021)

Dalpiciclib partially abrogates ER signaling activation induced by pyrotinib in HER2(+)HR(+) breast cancer
por: Bu, Jiawen, et al.
Publicado: (2023)

Adjuvant Olaparib for Germline BRCA Carriers With HER2-Negative Early Breast Cancer: Evidence and Controversies
por: Morganti, Stefania, et al.
Publicado: (2023)

CD8(+) tumor‐infiltrating lymphocytes contribute to spontaneous “healing” in HER2‐positive ductal carcinoma in situ
por: Morita, Michi, et al.
Publicado: (2016)

New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified
por: MacNeil, Ian A., et al.
Publicado: (2020)

In utero and early-life exposure to thirdhand smoke causes profound changes to the immune system
por: Snijders, Antoine M., et al.
Publicado: (2021)

Predicting progression-free survival after systemic therapy in advanced head and neck cancer: Bayesian regression and model development
por: Barber, Paul R, et al.
Publicado: (2022)

Programmed death‐ligand 1 expression in gastric cancer: correlation with mismatch repair deficiency and HER2‐negative status
por: Wang, Lei, et al.
Publicado: (2018)

Structure and Dynamics of the EGF Receptor as Revealed by Experiments and Simulations and Its Relevance to Non-Small Cell Lung Cancer
por: Martin-Fernandez, Marisa L., et al.
Publicado: (2019)

HER2 copy number as predictor of disease-free survival in HER2-positive resectable gastric adenocarcinoma
por: Liu, Zimin, et al.
Publicado: (2021)

HER2-HER3 Heterodimer Quantification by FRET-FLIM and Patient Subclass Analysis of the COIN Colorectal Trial
por: Barber, Paul R, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_kgog6lbl0i5836r3srh3m0bd8a